Spec­trum hits the re­set but­ton, slic­ing away 30% of its work­force in piv­ot around 2 lead as­sets

Covid-19 has been a rough go for many drugmakers, but few more so than Spectrum Pharmaceuticals, which has seen inspection delays and unwanted CRLs haunt its chance at a first approval. Feeling the sting, Spectrum will now downsize to keep the lights on through the year.